Redeye: Cellavision Q1 2025 - EMEA Drove Sales Growth
Redeye comments on Cellavision's first quarter 2025, which saw organic sales growth of 14%, an outstanding figure. Growth was mainly driven by instrument sales in EMEA. The outlook for the rest of the year is positive, with the caveat that an appreciating SEK will have a negative effect on the final growth rate.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/